Analysis of antibody kinetics after vaccination with mRNA-1273 and factors influencing the vaccine immunogenicity
We conducted a prospective study on healthy young adults who were to receive two doses of mRNA-1273 vaccine at 28-day intervals. After each dose, adverse events were prospectively evaluated, and blood samples were collected. The correlation between humoral immune response and reactogenicity after vaccination was determined. In addition, long-term anti-SARS-CoV-2 antibody kinetics will be assessed.
Study Type
OBSERVATIONAL
Enrollment
179
two doses of mRNA-1273 vaccine at 28-day intervals
Catholic Kwandong University
Incheon, South Korea
RECRUITINGKangnam Sacred Heart Hospital
Seoul, South Korea
RECRUITINGKorea University Anam Hospital
Seoul, South Korea
The correlation between humoral immune response and reactogenicity after vaccination
The correlation between humoral immune response and reactogenicity after vaccination
Time frame: The correlation between reactogenicity after dose 1 and immunogenicity at T1 (28 days after dose 1 prior to the 2nd dose) and T2 (28 days after dose 2); the correlation between reactogenicity after vaccine dose 2 and immunogenicity at T2
anti-SARS-CoV-2 antibody
SARS-CoV-2 immunoglobulin G (IgG) assay (Abbott Laboratories, Chicago, IL, USA)
Time frame: before vaccination (T0), 28 days after the first dose prior to the second dose (T1), and 28 days after the second dose (T2)
neutralizing antibody titer
plaque reduction neutralization test was performed using wild-type SARS-CoV-2 virus (BetaCoV/Korea/KCDC03/2020)
Time frame: before vaccination (T0), 28 days after the first dose prior to the second dose (T1), and 28 days after the second dose (T2)
reactogenicity after vaccination
record the occurrence, severity, and duration of solicited AEs using a standardized electronic questionnaire
Time frame: Seven days after each dose of vaccine
Long-term persistence of anti-SARS-CoV-2 antibody and neutralizing antibody titer
SARS-CoV-2 immunoglobulin G (IgG) assay (Abbott Laboratories, Chicago, IL, USA); plaque reduction neutralization test was performed using wild-type SARS-CoV-2 virus (BetaCoV/Korea/KCDC03/2020)
Time frame: At 3 months and 6 months after dose 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Korea University Guro Hospital, International St. Mary's Hospital, Gangnam Sacred Heart Hospital, Ajou University School of Medicine, Korea University Anam Hospital
Seoul, South Korea
RECRUITINGAjou University School of Medicine Hallym University
Suwon, South Korea
RECRUITING